Eine Kamera ist auf eine reflektierende Glasscheibe gerichtet.
© DZIF

News

All current DZIF news can be found here.

Prof. Dr. Anna Hirsch und Dr. Walid A. M. Elagher
© HIPS/Hartman

Breathing easy thanks to new antibiotics

New active substances for the treatment of resistant bacteria are needed more urgently than ever – yet only few candidates make the leap from research to clinical application. To facilitate precisely

Impfstoffentwicklung
© Universität Tübingen / Paul Mehnert

Therapeutic Vaccine for Chronic Hepatitis B Enters Clinical Trial

TherVacB, a novel therapeutic vaccine to combat chronic hepatitis B, entered the first clinical trial. The vaccine was designed and developed under the leadership of Helmholtz Munich. This phase 1a

Tubercle bacilli
© cdc/James Archer

Developing novel strategies against tuberculosis and malaria

Tuberculosis and malaria are among the deadliest infectious diseases worldwide and are increasingly spreading, not least due to climate change. In both cases, antimicrobial resistance renders

Tuberkulosemedikamente
© FZ Borstel

New active agent for the treatment of tuberculosis

A recent clinical study shows that ganfeborole could be a promising candidate for the safe and effective treatment of pulmonary tuberculosis. Using microbiological testing and innovative imaging

EBV-Viren in Zellen
© CDC/Dr. P. Feorino

Epstein-Barr Virus: Molecular Mechanism of Lymphoma Development Elucidated

Epstein-Barr Virus (EBV) is widespread and very contagious: according to the World Health Association, more than 90 percent of the global population are infected with this virus throughout their lives

Logo of World NTD Day, showing a stylized sun and the text lines "30 January - World NTD Day - Neglected Tropical Diseases" in white on a red background
© World NTD Day

30 January—World Neglected Tropical Diseases Day

The World Neglected Tropical Diseases Day on 30 January under the motto UNITE.ACT.ELIMINATE draws attention to neglected tropical diseases (NTDs) and the suffering they cause. More than one billion

Nebeneinanderstehende Logos von AiCuris und DZIF auf einem weiß-blauen Hintergrund, auf dem ein Füllfederhalter mit der Spitze auf ein Papier gerichtet ist.
© DZIF

AiCuris and the German Center for Infection Research (DZIF) sign Collaboration and License Option Agreement

AiCuris Anti-infective Cures AG and the German Center for Infection Research (DZIF) have announced the signing of a collaboration and license option agreement today. As part of the collaboration, DZIF

Petri dish
© DZIF/scienceRELATIONS

BioVersys AG and Helmholtz Centre for Infection Research join forces to accelerate AMR research and development

BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug

Prof Dr. Harald Seifert
© Uniklinik Köln

New treatment options for bloodstream infections

Study shows efficacy and safety of oral antibiotic therapy in the form of pills for Staphylococcus aureus bloodstream infections. Currently, infusions are the standard treatment / published in ‘The

Red-coloured rod-shaped bacteria in an electron micrograph.
© CDC

Treating tuberculosis when antibiotics no longer work

Tuberculosis is currently the infectious disease that causes the most deaths worldwide. Of particular concern is the increasing emergence of multidrug-resistant tuberculosis bacteria, particularly in